Codexis (CDXS) Competitors

Myriad Genetics (NASDAQ:MYGN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.

Is MYGN or CDXS more profitable?

Myriad Genetics has a net margin of -14.09% compared to Codexis' net margin of -96.35%. Myriad Genetics' return on equity of -4.51% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-14.09%	-4.51%	-3.07%
Codexis	-96.35%	-71.56%	-38.00%

Does the media refer more to MYGN or CDXS?

In the previous week, Myriad Genetics had 1 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Myriad Genetics and 5 mentions for Codexis. Codexis' average media sentiment score of 0.55 beat Myriad Genetics' score of 0.41 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in MYGN or CDXS?

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by company insiders. Comparatively, 2.1% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts rate MYGN or CDXS?

Myriad Genetics currently has a consensus price target of $22.54, indicating a potential upside of 58.11%. Codexis has a consensus price target of $8.33, indicating a potential upside of 96.77%. Given Codexis' stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.07
Codexis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the MarketBeat Community believe in MYGN or CDXS?

Myriad Genetics received 121 more outperform votes than Codexis when rated by MarketBeat users. However, 61.47% of users gave Codexis an outperform vote while only 52.97% of users gave Myriad Genetics an outperform vote.

Company	Underperform	Outperform
Myriad Genetics	Outperform Votes 472 52.97%	Underperform Votes 419 47.03%
Codexis	Outperform Votes 351 61.47%	Underperform Votes 220 38.53%

Which has more risk and volatility, MYGN or CDXS?

Myriad Genetics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.

Which has preferable valuation and earnings, MYGN or CDXS?

Codexis has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$753.20M	1.72	-$263.30M	-$1.30	-10.97
Codexis	$70.14M	4.91	-$76.24M	-$0.87	-4.87

Summary

Codexis beats Myriad Genetics on 9 of the 17 factors compared between the two stocks.